Skip to content

Early Lung Cancer Detection in Patients With Sputum Cytology and Autofluorescence Bronchoscopy in People at High Risk of Lung Cancer

Early Lung Cancer Detection in Patients With Sputum Cytology and Autofluorescence Bronchoscopy in People at High Risk of Lung Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00563420
Enrollment
400
Registered
2007-11-26
Start date
2002-11-30
Completion date
2007-06-30
Last updated
2013-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasms

Keywords

Lung cancer

Brief summary

Lung cancer is the commonest malignant disease with a 5-year survival of 14%. In Hong Kong, it accounts for about 30% of all cancer death. The poor prognosis of lung cancer is due largely to the late clinical presentation of the disease. In order to improve the prognosis of lung cancer, an obvious approach is to develop sensitive methods for detecting lung cancer at much earlier stages when treatment is more likely to be curative. However, the best way for identifying early lung cancer is still need to be determined. We hypothesis that by examining specimens that contain shed bronchial epithelial cells i.e. sputum, lung cancer can be sampled in its earliest possible phase. And by using autofluorescence bronchoscopy, a system specifically designed to detect early lung cancer/pre-invasive lesions, to identify the source of abnormal cells, we may able to detect eraly lung cancer and followed by curative treatment to improve the prognosis of this disease.

Interventions

PROCEDUREBronchoscopy

Sponsors

Hospital Authority, Hong Kong
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Primary purpose
DIAGNOSTIC

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum

Inclusion criteria

* Current or ex-smokers who have smoked at least 20-pack-years (e.g. 1 pack per day for 20 years or more) * Informed consent

Exclusion criteria

* Known malignant disease * Unstable major medical disease * Bleeding disorder * Unwilling to have a bronchoscopy * Women currently pregnant or nursing * Known reaction to xylocaine, a local anaesthesia agent used for bronchoscopy

Design outcomes

Primary

MeasureTime frame
Number of early stage lung cancer/precancerous lesion detectedTwo years

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026